Compare Neoadjuvant Chemotherapy of DOS Versus SOX in Locally Advanced Gastric Adenocarcinoma. (RESOLVE-2)

• ClinicalTrials.gov Identifier: NCT03691454
• Recruitment Status: Active, not recruiting
• First Posted: October 1, 2018
• Last Update Posted: October 1, 2018
• Sponsor: Peking University
• Information provided by (Responsible Party): Shen Lin, Peking University

Study Description

Brief Summary:

This is a randomized, multicenter, controlled, adaptive phase II/III clinical study. The aim is to compare neoadjuvant chemotherapy of Docetaxel，Oxaliplatin combined with S-1(DOS) versus Oxaliplatin combined with S-1(SOX) in locally advanced gastric adenocarcinoma

Condition or disease	Intervention/treatment	Phase
Gastric Adenocarcinoma	Drug: Docetaxel; Drug: Oxaliplatin	Phase 2; Phase 3

Detailed Description:

This trial is conducted in patients with locally advanced gastric adenocarcinoma. Eligible patients are randomized into two arms at 1:1 ratio to receive Docetaxel, Oxaliplatin combined with S-1(DOS) for 4 cycles or Oxaliplatin combined with S-1(SOX) for 3 cycles as neoadjuvant chemotherapy. All eligible patients will receive D2 gastrectomy if possible. Then, all eligible patients will also received DOS for 4 cycles or SOX for 3 cycles within 8 weeks after surgery. Study evaluation time is until death of patients or deadline set by the researchers.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 258 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Randomized, Multicenter, Controlled, Adaptive II/III Study to Compare Neoadjuvant Chemotherapy of Docetaxel，Oxaliplatin Combined With S-1(DOS) Versus Oxaliplatin Combined With S-1(SOX)in Locally Advanced Gastric Adenocarcinoma (RESOLVE-2 Study)
• Actual Study Start Date: June 28, 2018
• Estimated Primary Completion Date: June 30, 2022
• Estimated Study Completion Date: June 30, 2023

Arms and Interventions

Arm	Intervention/treatment
Experimental: DOS; Docetaxel+Oxaliplatin+S-1	Drug: Docetaxel; Docetaxel 50mg/m2, intravenous drip, D1, combined with Oxaliplatin 85mg/m2，intravenous drip 2h，D1 and S-1 40-60mg bid(BSA<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2, 50mg bid, BSA>1.5m2, 60mg bid)，D1-7；For patients with Her2 positive, add Herceptin 4mg/kg(6mg/kg first cycle) D1; every 14 days for a cycle.; Other Names: Oxaliplatin; S-1; Herceptin
Active Comparator: SOX; Oxaliplatin+S-1	Drug: Oxaliplatin; Oxaliplatin 130mg/m2，intravenous drip 2h，D1 combined with S-1 40-60mg bid(BSA<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2, 50mg bid, BSA>1.5m2, 60mg bid)，D1-14；For patients with Her2 positive, add Herceptin 6mg/kg(8mg/kg first cycle) D1; every 21 days for a cycle.; Other Names: S-1; Herceptin

Outcome Measures

Primary Outcome Measures :

1. The rate of pathologic complete response（pCR%） [ Time Frame: 1 year ]
   Evaluation of pCR% of DOS regimen versus SOX regimen in locally advanced gastric adenocarcinoma

Secondary Outcome Measures :

1. Overall Survival : From date of enrollment until the date of death [ Time Frame: 5 years ]
   Evaluation of the Overall Survival of DOS regimen versus SOX regimen in locally advanced gastric adenocarcinoma
2. Progression-free Survival：From date of enrollment until the date of first documented progression or second gastric cancer or death from any cause, whichever came first. [ Time Frame: 3 years ]
   Evaluation of the Progression-free Survival of DOS regimen versus SOX regimen in locally advanced gastric adenocarcinoma

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Ambulatory males or females with ages ≥ 18.
2. Karnofsky performance status ≥ 70%.
3. Histologically confirmed gastric adenocarcinoma including Lauren classification and validated overexpression of HER2.
4. cTNM should be diagnosed by enhanced CT/MRI (combined with endoscopic ultrasonography and diagnostic laparoscopic exploration) as cIII/IVa according to AJCC 8th classification.
5. Radical resection is possible before operation.
6. Research center and surgeons have the ability of conducting D2 lymphadenectomy (more than 15 lymph glands should be checked to ensure the quality of operation).
7. Physiological status and organ function are acceptable for major abdominal surgical operation.
8. Baseline blood routine and biochemical indexes of patients enrolled should meet criteria below: hemoglobin ≥ 90g/L, absolute neutrophil count ≥ 1.5×10⁹/L, platelet count ≥ 100×10⁹/L, aspartate or alanine aminotransferase ≤ 2.5 times the upper limit of normal (ULN), alkaline phosphatase ≤ 2.5 times the ULN, total serum bilirubin < 1.5 times the ULN, serum creatinine < 1 time ULN, Serum albumin ≥ 30g/L.
9. Left ventricular ejection fraction evaluated by echocardiac scanning ≥ 50%.
10. No severe comorbidity with less than 5 year survival.
11. Willing to receive the regimens in this study.
12. Sign written informed consent form before screening of study, and can withdraw in any time with no loss.
13. Agree to provide blood sample and histological specimen.

Exclusion Criteria：

1. Pregnancy or lactation women.
2. Woman of childbearing age was not tested in baseline pregnancy test or tested positve. Postmenopausal women with amenorrhea for at least 12 months are considered nonpregnancy.
3. Sexually active males or females refuse to practice contraception during the study.
4. With distant metastasis diagnosed by CT/EUS.
5. Underwent prior antitumor treatment including chemotherapy, radiotherapy or immunotherapy except steroid therapy.
6. Suffered from other malignant tumors in previous 5 years, with the exception of cured cutaneum carcinoma and cervical carcinoma in situ.
7. Patients with uncontrolled seizure, central nervous system disorder or psychiatric disease will be judged by researchers whether severity influences signing informed consent or compliance to take medicine.
8. Suffered from severe cardiovascular diseases such as symptomatic coronary heart disease, congestive heart failure ≥ II grade according to NYHA (New York Heart Association) standard, uncontrolled cardiac arrhythmia, cardiac infarction within 12 months prior to study enrollment.
9. Complicated by upper gastrointestinal obstruction or abnormal digestive function or malabsorption syndrome, which may affect the absorption of S-1.
10. Known peripheral nervous system disorder ≥ NCI CTC AE 1 grade with the exception of only disappearance of deep tendon reflex (DRT).
11. History of organ transplantation with immunosuppression therapy.
12. Complicated with severe uncontrolled concurrent infection or other severe uncontrolled concominant diseases, moderate or severe kidney injury (creatinine clearance rate ≤ 50 ml/min according to Cockcroft and Gault formula), or serum creatinine serum > the upper limit of normal (ULN)
13. Lack of dihydropyrimidine dehydrogenase (DPD).
14. Allergic reaction to platinum compounds or other agents used in this study.
15. Patients who have received study agents within 4 weeks (participating in other clinical trials).

Contacts and Locations

Locations

China, Beijing

Beijing Cancer Hospital

Beijing, Beijing, China, 100142

Sponsors and Collaborators

Peking University

Investigators

• Principal Investigator: Jiafu Ji, Professor; Beijing Cancer Hospital

More Information

• Responsible Party: Shen Lin, Head of Beijing Cancer Hospital, Peking University
• ClinicalTrials.gov Identifier: NCT03691454
• Other Study ID Numbers: CGOG1008
• First Posted: October 1, 2018
• Last Update Posted: October 1, 2018
• Last Verified: September 2018

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Shen Lin, Peking University:

gastric adenocarcinoma; neoadjuvant chemotherapy; locally advanced; Oxaliplatin; S-1; Docetaxel

Additional relevant MeSH terms:

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Docetaxel; Oxaliplatin; Trastuzumab; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents, Immunological